ClinicalTrials.gg
RecruitingNCT047773573112 Ped BPDUpdated Jul 27, 2026

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

A Phase 3 interventional study of Cariprazine and Placebo in Depression and Bipolar I Disorder, sponsored by AbbVie. Recruiting at 81 sites in 3 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing cariprazine in Depression — 1 open to participants now, 2 under way, 1 of them phase 3. cariprazine · Depression.

Planned enrollment
8th of 11
380 · median 488
Started
2021
with 1 other
Phase 3
5 of 11
1 open now
Registered
9th of 11
by date
Lead sponsor
3 of 11
AbbVie

Among the 11 studies testing cariprazine in Depression, this one is the 8th largest by planned enrollment, is one of 2 that started in 2021, is one of 5 in phase 3, and was the 9th registered.

Depression

8,595 studies on the registry are indexed under Depression; 1,728 are open to participants now.

Browse Depression studies →

Open to participants now

1 of the 11 studies testing cariprazine in Depression is open now, in 3 countries.

By country, each count listing its studies:

About cariprazine

cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,090 Depression studies recruiting now, 470 (43%) set no upper age limit and 520 (48%) stop at 75 or younger; 203 take children under 18; 311 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing cariprazine in Depression, or all of them as a file.
02

Study summary

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States. The treatment of the depressive episodes of bipolar disorder in the pediatric population has not been as widely studied as the treatment of depressive episodes in bipolar disorder in adults, therefore pharmacotherapeutic options are limited. Given the change in disease state and safety demonstrated in adults with depressive episodes associated with bipolar I disorder, the purpose of this study is to evaluate the change in disease state and safety of cariprazine in the treatment of depressive episodes associated with bipolar I disorder in the pediatric population.

Cariprazine is an approved drug for the treatment of depressive episodes in adult participants with bipolar I disorder. Study doctors put participants in 1 of 2 groups, called treatment arms. There is a 1 in 2 chance that a participant will be assigned to placebo. Around 380 Participants ages 10-17 years with bipolar I disorder will be enrolled in approximately 60 sites worldwide.

Participants receiving the study drug will receive Dose A or B of Cariprazine based on age and weight. At Week 3, participants with insufficient response will have their dose increased to Dose B or Dose C, while participants with sufficient response will continue receiving the Dose A or B for the remainder of the treatment period. The treatment period will be followed by a safety follow-up (SFU) period for 4 weeks.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Depression
  • Bipolar I Disorder

Browse trials for

Keywords

  • Depression
  • RGH-188
  • Bipolar I Disorder
  • Vraylar
  • Cariprazine
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with , Fifth Edition (DSM-5) primary diagnosis of bipolar I disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL).
  • Current depressive episode is more than 2 weeks and less than 12 months in duration.
  • Participant has a lifetime history of at least one manic episode.
  • Children's Depression Rating Scale - Revised (CDRS-R) score > = 45 at Visit 1 and Visit 2.
  • Young-Mania Rating Scale (YMRS) score \< = 12 with YMRS Item 1 (elevated mood) score \< = 2 at Visit 1 and Visit 2.
  • Clinical Global Impression-Severity (CGI-S) scale score of > = 4 (moderately ill) at Visit 1 and Visit 2.

Exclusion criteria

Exclusion Criteria:

  • Participants with diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, psychotic disorder due to another medical condition, PTSD, antisocial personality disorder, or borderline personality disorder.
  • Participant has a history of meeting DSM-5 diagnosis for any substance-related disorder (except caffeine- and tobacco-related) within the 3 months before Screening Visit 1.
  • History of serotonin syndrome or neuroleptic malignant syndrome.
  • Four or more episodes of a mood disturbance within the 12 months before Visit 1.
  • DSM-5 diagnosis of intellectual disability (IQ \< 70), autism spectrum disorders, or documented history of chromosomal disorder with developmental impairment.
  • History of seizures, with the exception of febrile seizures.
  • Significant head trauma, history of tumor of the CNS, or any other condition that predisposes to seizures.
  • Participant requires concomitant treatment with moderate or strong inhibitors or with any CYP3A4 inducers.
  • Participant requires concomitant treatment with any prohibited medication, supplement, or herbal product, including any psychotropic drug or any drug with psychotropic activity or with a potentially psychotropic component.
  • Use of a depot antipsychotic within 2 cycles of their respective dosing interval prior to Screening Visit 1.
  • Treatment with clozapine in a dose of >= 50 mg/d in the past 2 years.
  • History of or any current ocular disease including, but not limited to, retinal detachment, intraocular surgery, laser treatment, glaucoma, cataracts, or ocular trauma (with the exception of refractive errors).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
380 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive Placebo over a 6 week treatment period.

    Drug: Placebo

  • Experimental
    Cariprazine

    Participants will receive flexible dose Cariprazine over a 6 week treatment period.

    Drug: Cariprazine

Interventions

  • Oral Capsule

    Also known as: Vraylar

  • DrugPlacebo

    Oral Capsule

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a casual relationship with this treatment. The investigator assesses the relationship of each event to the use of the study. A serious adverse event (SAE) is an event that results in death, is life threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event, that based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/ treatment emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of the study drug.

    Time frame: Baseline (Week 0) to Week 10

  2. Abnormal Change from Baseline in Vital Signs

    Change in vital signs like systolic and diastolic blood pressure will be assessed.

    Time frame: Baseline (Week 0) to Week 10

  3. Number of Participants with Incidence of Abnormal Clinical Laboratory Test Results

    Number of participants with incidence of abnormal clinical laboratory test results like hematology will be assessed.

    Time frame: Baseline (Week 0) to Week 6

  4. Change in Electrocardiogram (ECG)

    12 -lead resting ECGs will be recorded. Parameters include RR interval, PR interval, QT interval, and QRS duration.

    Time frame: Baseline (Week 0) to Week 6

  5. Change From Baseline in Simpson-Angus Scale (SAS)

    SAS is a 10-item rating scale for assessment of antipsychotic-induced parkinsonism in both clinical practice and research settings. Each item ranges from 0 (normal) to 4 (extreme symptoms). The scale consists of 1 item measuring gait (hypokinesia), 6 items measuring rigidity, and 3 items measuring glabella tap, tremor, and salivation, respectively.

    Time frame: Baseline (Week 0) to Week 6

  6. Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior.

    Time frame: Baseline (Week 0) to Week 10

  7. Change From Baseline in Barnes Akathisia Rating Scale (BARS)

    BARS is a 4-item rating scale used to assess drug-induced akathisia. The scale comprises items for rating the observable restless movements that characterize the condition, the subjective awareness of restlessness, and any distress associated with the akathisia (each on a 4-point scale from normal \[0\] to severe \[3\]). In addition, there is a global severity for akathisia rated on a 6-point scale (absent \[0\] to severe akathisia \[5\]).

    Time frame: Baseline (Week 0) to Week 6

  8. Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)

    AIMS assesses abnormal involuntary movements, such as tardive dyskinesia, associated with antipsychotic drugs; it measures facial, oral, extremities, and trunk movements, as well as the participant's awareness of abnormal movements. The first 10 items are rated on a none (0) to severe (4) scale. There are an additional 2 items on dental status that are answered yes or no.

    Time frame: Baseline (Week 0) to Week 6

  9. Change in Children's Depression Rating Scale - Revised (CDRS-R) Total Score

    The CDRS-R is a 17-item clinician-administered scale specifically developed for the assessment of depressive symptoms in children and adolescents. Total scores range from 17 to 113. In general, scores below 20 indicate an absence of depression, scores of 20 to 30 indicate borderline depression, and scores of 40 to 60 indicate moderate depression. The CDRS-R will be administered by a clinician with extensive professional training in mental illness.

    Time frame: Baseline (Week 0) to Week 6

07

Study locations

32 of 81 sites recruiting
  • Pillar Clinical Research /ID# 226504
    Bentonville, Arkansas 72712, United States
    Completed

    Not enrolling at this site — choose another above.

  • Advanced Research Center /ID# 227073
    Anaheim, California 92805, United States
    Recruiting
  • Care Access Research /ID# 226316
    Beverly Hills, California 90212, United States
    Completed

    Not enrolling at this site — choose another above.

  • Inland Pyschiatric Medical Group - Chino /ID# 278667
    Chino, California 91710, United States
    Recruiting
  • ProScience Research Group /ID# 226223
    Culver City, California 90230-6632, United States
    Completed

    Not enrolling at this site — choose another above.

  • National Institute of Clinical Research - Garden Grove /ID# 262835
    Garden Grove, California 92844, United States
    Completed

    Not enrolling at this site — choose another above.

  • Accellacare - Long Beach /ID# 279482
    Long Beach, California 90807, United States
    Recruiting
  • Duplicate_Alliance for Research - Long Beach /ID# 226522
    Long Beach, California 90807, United States
    Completed

    Not enrolling at this site — choose another above.

  • CHOC Children's Hospital /ID# 260298
    Orange, California 92868-4203, United States
    Recruiting
  • ATP Clinical Research- Orange /ID# 253719
    Orange, California 92868, United States
    Completed

    Not enrolling at this site — choose another above.

  • Prospective Research Innovations Inc /ID# 240774
    Rancho Cucamonga, California 91730, United States
    Completed

    Not enrolling at this site — choose another above.

  • Inland Psychiatric Medical Group /ID# 274621
    Redlands, California 92373, United States
    Recruiting
  • University of California Davis Health /ID# 268306
    Sacramento, California 95817, United States
    Recruiting
  • University of California, San Diego Department of Psychiatry /ID# 226463
    San Diego, California 92103-8229, United States
    Completed

    Not enrolling at this site — choose another above.

  • Lumos Clinical Research Center /ID# 262805
    San Jose, California 95124-4108, United States
    Completed

    Not enrolling at this site — choose another above.

  • Pacific Clinical Research Management Group /ID# 227075
    Upland, California 91786, United States
    Completed

    Not enrolling at this site — choose another above.

  • Next Level Clinical Trials /ID# 277152
    West Covina, California 91790, United States
    Recruiting
  • D&H Doral Research Center-Doral /ID# 255458
    Doral, Florida 33122, United States
    Recruiting
  • Advanced Research Institute of Miami /ID# 228222
    Homestead, Florida 33030-4613, United States
    Completed

    Not enrolling at this site — choose another above.

  • Columbus Clinical Services, Llc /Id# 229792
    Miami, Florida 33125, United States
    Completed

    Not enrolling at this site — choose another above.

  • G+C Research Group, LLC /ID# 261399
    Miami, Florida 33126-2018, United States
    Completed

    Not enrolling at this site — choose another above.

  • Florida Research Center, Inc. /ID# 240775
    Miami, Florida 33174, United States
    Recruiting
  • South Florida Research Ph I-IV /ID# 240778
    Miami Springs, Florida 33166-7225, United States
    Completed

    Not enrolling at this site — choose another above.

  • Medical Research Group of Central Florida /ID# 256757
    Orange City, Florida 32763, United States
    Recruiting
  • APG Research, LLC /ID# 226519
    Orlando, Florida 32803, United States
    Completed

    Not enrolling at this site — choose another above.

  • Nova Psychiatry Inc. /ID# 270892
    Orlando, Florida 32803, United States
    Recruiting
  • Panhandle Research and Medical Clinic, LLC /ID# 268522
    Pensacola, Florida 32502, United States
    Completed

    Not enrolling at this site — choose another above.

  • D&H Tamarac Research Center /ID# 250434
    Tamarac, Florida 33321-2979, United States
    Recruiting
  • University of South Florida- Neuroscience Institute /ID# 246508
    Tampa, Florida 33613, United States
    Completed

    Not enrolling at this site — choose another above.

  • Atlanta Center for Medical Research /ID# 226480
    Atlanta, Georgia 30331, United States
    Completed

    Not enrolling at this site — choose another above.

  • CenExcel iResearch LLC /ID# 228695
    Decatur, Georgia 30030, United States
    Recruiting
  • Atlanta Behavioral Research, LLC /ID# 226486
    Dunwoody, Georgia 30338, United States
    Completed

    Not enrolling at this site — choose another above.

  • Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 226371
    Stockbridge, Georgia 30281, United States
    Completed

    Not enrolling at this site — choose another above.

  • Denali Health Atlanta, LLC /ID# 278167
    Stone Mountain, Georgia 30083, United States
    Recruiting
  • Duplicate_Ascension St. Elizabeth /ID# 240772
    Chicago, Illinois 60622, United States
    Completed

    Not enrolling at this site — choose another above.

  • Baber Research Group /ID# 232279
    Naperville, Illinois 60563-6502, United States
    Completed

    Not enrolling at this site — choose another above.

  • Advanced Quality Medical Research /ID# 272902
    Orland Park, Illinois 60462, United States
    Recruiting
  • Indiana University /ID# 260705
    Indianapolis, Indiana 46202-3082, United States
    Completed

    Not enrolling at this site — choose another above.

  • Benchmark Research /ID# 260714
    Shreveport, Louisiana 71101, United States
    Completed

    Not enrolling at this site — choose another above.

  • The Kennedy Krieger Institute /ID# 226509
    Baltimore, Maryland 21205, United States
    Completed

    Not enrolling at this site — choose another above.

  • Med Clinical Research Partners LLC /ID# 240773
    Irvington, New Jersey 07111, United States
    Recruiting
  • Duplicate_NeuroCognitive and Behavioral Institute, Inc /ID# 227077
    Mount Arlington, New Jersey 07856-1315, United States
    Completed

    Not enrolling at this site — choose another above.

  • UB Department of Psychiatry /ID# 226373
    Buffalo, New York 14215, United States
    Completed

    Not enrolling at this site — choose another above.

  • New Dawn Psychiatric Services PLLC /ID# 229782
    Kinston, North Carolina 28501-1603, United States
    Completed

    Not enrolling at this site — choose another above.

  • Quest Therapeutics of Avon Lake /ID# 226349
    Avon Lake, Ohio 44012, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of Cincinnati /ID# 226465
    Cincinnati, Ohio 45219, United States
    Completed

    Not enrolling at this site — choose another above.

  • Cleveland Clinic - Cleveland /ID# 276309
    Cleveland, Ohio 44195, United States
    Recruiting
  • CincyScience /ID# 226318
    West Chester, Ohio 45069, United States
    Recruiting
  • IPS Research Company /ID# 227072
    Oklahoma City, Oklahoma 73106, United States
    Completed

    Not enrolling at this site — choose another above.

  • SP Research, PLLC /ID# 259428
    Oklahoma City, Oklahoma 73112-8729, United States
    Completed

    Not enrolling at this site — choose another above.

  • Cutting Edge Research Group /ID# 240777
    Oklahoma City, Oklahoma 73116-1423, United States
    Completed

    Not enrolling at this site — choose another above.

  • Paradigm Research Professionals /ID# 260719
    Oklahoma City, Oklahoma 73116, United States
    Completed

    Not enrolling at this site — choose another above.

  • Sooner Clinical Research /ID# 226384
    Oklahoma City, Oklahoma 73116, United States
    Recruiting
  • BioBehavioral Research of Austin /ID# 227076
    Austin, Texas 78759, United States
    Completed

    Not enrolling at this site — choose another above.

  • Beaumont Psychiatric Clinic /ID# 267484
    Beaumont, Texas 77706, United States
    Recruiting
  • Houston Clinical Trials - Bellaire /ID# 274189
    Bellaire, Texas 77401, United States
    Recruiting
  • Texas Research Group /ID# 270050
    Coppell, Texas 75019, United States
    Recruiting
  • Relaro Medical Trials /ID# 227156
    Dallas, Texas 75243, United States
    Recruiting
  • Earle Research /ID# 253782
    Friendswood, Texas 77546, United States
    Recruiting
  • McGovern Medical School /ID# 240779
    Houston, Texas 77054, United States
    Completed

    Not enrolling at this site — choose another above.

  • Southwest Biomed Research Center LLC /ID# 226340
    Houston, Texas 77063, United States
    Completed

    Not enrolling at this site — choose another above.

  • Kaleidoscope Clinical Research /ID# 277650
    Houston, Texas 77089, United States
    Recruiting
  • Red Oak Psychiatry Associates /ID# 240776
    Houston, Texas 77090-2641, United States
    Completed

    Not enrolling at this site — choose another above.

  • Livingspring Family Medical Center /ID# 262706
    Mansfield, Texas 76063-5622, United States
    Recruiting
  • Aim Trials /ID# 226367
    Plano, Texas 75093, United States
    Recruiting
    • Site Coordinator · Contact214-856-2778
  • Perceptive Pharma Research /ID# 262219
    Richmond, Texas 77407, United States
    Recruiting
  • Family Psychiatry of The Woodlands /ID# 226290
    The Woodlands, Texas 77381, United States
    Recruiting
  • Pantheon Clinical Research /ID# 270879
    Bountiful, Utah 84010, United States
    Recruiting
  • Core Clinical Research /ID# 226374
    Everett, Washington 98201, United States
    Recruiting
  • Dr. Samuel Sanchez PSC /ID# 245952
    Caguas, 00727, Puerto Rico
    Completed

    Not enrolling at this site — choose another above.

  • GCM Medical Group /ID# 245951
    San Juan, 00917-3104, Puerto Rico
    Recruiting
  • Clinica of Glazunova /ID# 229416
    Krasnodar, Krasnodarskiy Kray 350051, Russia
    Completed

    Not enrolling at this site — choose another above.

  • Duplicate_Scientific Centre of Personalized Medicine /ID# 226380
    Moscow, Moscow 105082, Russia
    Completed

    Not enrolling at this site — choose another above.

  • Duplicate_Central Clinical Psychiatric Hospital /ID# 226381
    Moscow, Moscow 127083, Russia
    Completed

    Not enrolling at this site — choose another above.

  • Orenburg Regional Clinical Psychiatric Hospital #1 /ID# 226462
    Orenburg, Orenburg Oblast 460006, Russia
    Completed

    Not enrolling at this site — choose another above.

  • Psychotherapeutics Center Podderzhka /ID# 226348
    Stavropol, Stavropol Kray 355029, Russia
    Completed

    Not enrolling at this site — choose another above.

  • Clinical Psychiatry Hospital #1 of Nizhniy Novgorod /ID# 226226
    Nizhny Novgorod, 603155, Russia
    Completed

    Not enrolling at this site — choose another above.

  • Psychiatric hospital #1 /ID# 226516
    Saint Petersburg, 190121, Russia
    Completed

    Not enrolling at this site — choose another above.

  • National Medical Research Center of Psychiatry and Neurology n.a. V.M. Bekhterev /ID# 226515
    Saint Petersburg, 192019, Russia
    Completed

    Not enrolling at this site — choose another above.

  • Medgard Clinic /ID# 228598
    Saratov, 410028, Russia
    Completed

    Not enrolling at this site — choose another above.

  • Saratov City Clinical Hospital #2 n.a. V. I. Razumovsky /ID# 226222
    Saratov, 410028, Russia
    Completed

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Mar 2027, 71 months after the start.

Of 81 phase 3 interventional studies under Depression, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's planned 71 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2021
First posted
Mar 2, 2021
StartActual
Apr 28, 2021
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04777357
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 2, 2021
Start date
Apr 28, 2021
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jul 27, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion